Profound Medical Corp. 8-K Filing
Ticker: PROF · Form: 8-K · Filed: Apr 1, 2026 · CIK: 0001628808
| Field | Detail |
|---|---|
| Company | Profound Medical Corp. (PROF) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2026 |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Profound Medical Corp. (ticker: PROF) to the SEC on Apr 1, 2026.
How long is this filing?
Profound Medical Corp.'s 8-K filing is 2 pages with approximately 555 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 555 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2026-04-01 08:29:01
Filing Documents
- f8k_040126.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 11KB
- 0001171843-26-002146.txt ( ) — 223KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_040126_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On April 1, 2026, Profound Medical Corp. (the "Company" or "Profound") issued a press release announcing that the Company's interventional MRI TULSA Procedure will be highlighted in several presentations at the 2026 Society of Interventional Radiology Annual Scientific Meeting held in Toronto, ON, April 11-15, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated April 1, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROFOUND MEDICAL CORP. Date: April 1, 2026 By: /s/ Rashed Dewan Rashed Dewan Chief Financial Officer